Get Connected:

 

Latest News

Pharmacy Building into the Healthcare Ecosystem
Pharmacists with a collaborative practice agreement in place will play a larger role in the healthcare delivery team.
The National Diabetes Statistics Report found that 1 in 4 patients are unaware they have diabetes.
When cancerous cells die, they instruct neighboring cells to replace them.
Belimumab (Benlysta) in a subcutaneous treatment for active, autoantibody-positive systemic lupus erythematosus.
Lusduna Nexvue insulin glargine injection is a follow-on biologic for patients with type 2 diabetes.
Top news of the day from across the healthcare landscape.

Renflexis is indicated for the same inflammatory conditions as reference drug infliximab.
Top articles of the week from The American Journal of Pharmacy Benefits.
View More >

From the Journals

The cost of squamous cell cancer of the head and neck is driven primarily by the end-of-life phase. Treatment costs increased following the approval of cetuximab.
Given the need to provide patients with access to effective medications, it is likely that we will see more value-based contracts in the future; however, some key operational, communications, and regulatory barriers will need to be addressed first.
When making coverage decisions in oncology, payers find difficulties in translating evidence on treatment effect heterogeneity into coverage policies.    
The pharmacy benefit has begun to attract greater attention due to the increase in medications that are available and their cost. It is time we refocus on the needs of the patient and push ourselves and the benefit managers to evolve into a single integrated management and distribution model.
Among a population of adult patients with type 2 diabetes, adherence to oral hypoglycemic medications is independently associated with poor glycemic control, even after adjusting for patient-level covariates.

Adherence and access to higher-value care can make a big difference in reducing costs for patients and our healthcare system; however, the financial burden of high-deductible health plans and out-of-pocket costs must also be considered.

Patients with multiple chronic conditions are less likely to use generic drugs, even when facing lower co-payments.

Upcoming Partner Events